Pulmonary arterial hypertension and HIV infection

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 4, 2009, Pages 440-447

  Degano, Bruno ^a   Sitbon, Olivier ^a   Simonneau, Gérald ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Human immunodeficiency virus; Pulmonary arterial hypertension; Treatment

Indexed keywords

BOSENTAN; INDINAVIR; NEF PROTEIN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; RITONAVIR; SAQUINAVIR; SILDENAFIL;

ALGORITHM; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTINUOUS INFUSION; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFECT; DRUG METABOLISM; DYSPNEA; ENDOTHELIAL DYSFUNCTION; GENETIC PREDISPOSITION; HEART CATHETERIZATION; HEMODYNAMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LUNG EMBOLISM; MORBIDITY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW;

ALGORITHMS; ANIMALS; ANTI-HIV AGENTS; HEART CATHETERIZATION; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 68049104357     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1233313     Document Type: Review

References (64)

1. Grubb JR, Moorman AC, Baker RK, Masur H. The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy. AIDS 2006;20:1095-1107 (Pubitemid 43786097)
2. Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987;18:1293-1296
3. Opravil M, Pechère M, Speich R, et al. HIV-associated primary pulmonary hypertension: a case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155:990-995
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030
5. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433-1439 (Pubitemid 36609730)
6. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 1994;89:2722-2727 (Pubitemid 24173693)
7. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008;177:108-113
8. Hsue PY, Deeks SG, Farah HH, et al. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 2008;22:825-833 (Pubitemid 351563831)
9. Zuber JP, Calmy A, Evison JM, et al; Swiss HIV Cohort Study Group. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004;38:1178-1185
10. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS 2008;22(Suppl 3):S35-S40
11. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118:1133-1141
12. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-1271 (Pubitemid 23001268)
13. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43(12, Suppl S):25S-32S (Pubitemid 38759714)
14. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997;28:434-442 (Pubitemid 27175084)
15. Sztrymf B, Coulet F, Girerd B, et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008;177:1377-1383 (Pubitemid 351860916)
16. Caldwell RL, Gadipatti R, Lane KB, Shepherd VL. HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J Leukoc Biol 2006;79:192-201 (Pubitemid 43054265)
17. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11:554-559 (Pubitemid 28194842)
18. Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection: a possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992;145:1196-1200
19. Marecki JC, Cool CD, Parr JE, et al. HIV-1 nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006;174:437-445
20. Kanmogne GD, Primeaux C, Grammas P. HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia. J Neuropathol Exp Neurol 2005;64:498-505 (Pubitemid 40781152)
21. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436
22. Humbert M. Mediators involved in HIV-related pulmonary arterial hypertension. AIDS 2008;22(Suppl 3):S41-S47
23. Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 2002;5:141-151 (Pubitemid 36687517)
24. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996;124:654-663
25. Morse JH, Barst RJ, Itescu S, et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 1996;153(4 Pt 1):1299-1301 (Pubitemid 26112594)
26. Ascherl G, Hohenadl C, Schatz O, et al. Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy. Blood 1999;93:4232-4241 (Pubitemid 29279265)
27. Marecki J, Cool C, Voelkel N, Luciw P, Flores S. Evidence for vascular remodeling in the lungs of macaques infected with simian immunodeficiency virus/HIV NEF recombinant virus. Chest 2005;128(6, Suppl):621S-622S (Pubitemid 43054171)
28. Voelkel NF, Cool CD, Flores S. From viral infection to pulmonary arterial hypertension: a role for viral proteins? AIDS 2008;22(Suppl 3):S49-S53
29. Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003;349:1113-1122 (Pubitemid 37122323)
30. Henke-Gendo C, Mengel M, Hoeper MM, Alkharsah K, Schulz TF. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2005;172:1581-1585 (Pubitemid 43076549)
31. Montani D, Marcelin AG, Sitbon O, Calvez V, Simonneau G, Humbert M. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS 2005;19:1239-1240 (Pubitemid 41059271)
32. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000;40:282-284 (Pubitemid 30447185)
33. Petrache I, Diab K, Knox KS, et al. HIV associated pulmonary emphysema: a review of the literature and inquiry into its mechanism. Thorax 2008;63:463-469 (Pubitemid 351692357)
34. Thabut G, Dauriat G, Stern JB, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005;127:1531-1536 (Pubitemid 46218776)
35. McGoon M, Gutterman D, Steen V, et al; American College of Chest Physicians. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1, Suppl):14S-34S
36. Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009;33:92-98
37. Lebrec D. Methods to evaluate portal hypertension. Gastroenterol Clin North Am 1992;21:41-59
38. Lijfering WM, Ten Kate MK, Sprenger HG, van der Meer J. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. J Thromb Haemost 2006;4:1928-1930 (Pubitemid 44226770)
39. Heron E, Laaban JP, Capron F, Quieffin J, Brechot JM, Rochemaure J. Thrombotic primary pulmonary hypertension in an HIV+patient. Eur Heart J 1994;15:394-396 (Pubitemid 24127385)
40. Escamilla R, Hermant C, Berjaud J, Mazerolles C, Daussy X. Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser. Eur Respir J 1995;8:1982-1984
41. Montani D, Achouh L, Dorfmüller P, et al. Pulmonary venoocclusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008;87:220-233
42. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-2278
43. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928 (Pubitemid 46981654)
44. Hebert VY, Crenshaw BL, Romanoff RL, Ekshyyan VP, Dugas TR. Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol 2004;4:117-131 (Pubitemid 39310746)
45. Jiang B, Hebert VY, Zavecz JH, Dugas TR. Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defic Syndr 2006;42:391-395 (Pubitemid 44050884)
46. Pellicelli AM, Palmieri F, D'Ambrosio C, et al. Role of human immunodeficiency virus in primary pulmonary hypertension: case reports. Angiology 1998;49:1005-1011 (Pubitemid 29005671)
47. Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006;92:1164-1166 (Pubitemid 44125252)
48. Speich R, Jenni R, OpravilM, Jaccard R. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly 2001;131:663-665 (Pubitemid 34150443)
49. Bonora S, Lanzafame M, D'Avolio A, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 2008;46:146-147 (Pubitemid 351263577)
50. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111 (Pubitemid 40847788)
51. Glesby MJ, Aberg JA, Kendall MA, et al; Adult AIDS Clinical Trials Group A5159 Protocol Team. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005;78:143-153
52. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000;162:1846-1850
53. Limsukon A, Saeed AI, Ramasamy V, Nalamati J, Dhuper S. HIV-related pulmonary hypertension. Mt Sinai J Med 2006;73:1037-1044
54. Stricker H, Domenighetti G, Mombelli G. Prostacyclin for HIV-associated pulmonary hypertension. Ann Intern Med 1997;127:1043
55. Ghofrani HA, Friese G, Discher T, et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004;23:321-326 (Pubitemid 38202132)
56. Cea-Calvo L, Escribano Subías P, Tello de Menesses R, et al. Treatment of HIV-associated pulmonary hypertension with treprostinil [in Spanish]. Rev Esp Cardiol 2003;56:421-425 (Pubitemid 36608985)
57. Alp S, Schlottmann R, Bauer TT, Schmidt WE, Bastian A. Long-time survival with HIV-related pulmonary arterial hypertension: a case report. AIDS 2003;17:1714-1715 (Pubitemid 36951701)
58. Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002;16:1568-1569 (Pubitemid 34804229)
59. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001;15:1747-1748
60. Merry C, Barry MG, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS 1999;13:F101-F107 (Pubitemid 29509575)
61. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000;50:99-107
62. Sildenafil Summary of Product Characteristics. Available at: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID= 17443#CONTRAINDICATIONS
63. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212-1217 (Pubitemid 39577380)
64. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-344 (Pubitemid 47194187)